KR870007120A - 1,4-디히드로피리딘의 제조방법 - Google Patents

1,4-디히드로피리딘의 제조방법 Download PDF

Info

Publication number
KR870007120A
KR870007120A KR870000300A KR870000300A KR870007120A KR 870007120 A KR870007120 A KR 870007120A KR 870000300 A KR870000300 A KR 870000300A KR 870000300 A KR870000300 A KR 870000300A KR 870007120 A KR870007120 A KR 870007120A
Authority
KR
South Korea
Prior art keywords
alkyl
phenyl
dihydropyridine
formula
dimethyl
Prior art date
Application number
KR870000300A
Other languages
English (en)
Inventor
쥬라스지크 호르스트
게리케 랄프
루에스 잉게
베르그만 랄프
제이. 슈미트게스 클라우스
Original Assignee
노우만, 헤우만
메르크 파렌트 게젤샤프트 미트 베슈랭크터 하프퉁
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노우만, 헤우만, 메르크 파렌트 게젤샤프트 미트 베슈랭크터 하프퉁 filed Critical 노우만, 헤우만
Publication of KR870007120A publication Critical patent/KR870007120A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/82—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)

Abstract

내용 없음

Description

1,4-디히드로피리딘의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. 일반식(Ⅱ), (Ⅲ), (Ⅳ) 및 (Ⅴ)의 화합물 또는 이들의 작용성 유도체를 서로 반응시키고, 필요시, 공정단계에서, 또는 일반식(Ⅵ)의 티오아미드를 일반식(Ⅶ)의 카보닐 화합물과 반응시키거나, 또는 다음 일반식(Ⅷ)의 화합물을 다음 일반식(Ⅸ)의 화합물과 반응시키고/시키거나, 일반식(Ⅰ)의 화합물에서, 래디칼 R1,R2,R3,R4,R5및/또는 R6중 하나 또는 그 이상을 다른 래디칼 R1,R2,R3,R4,R5및/또는 R6로 전환시키고/시키거나, 일반식(Ⅰ)의 염기성 또는 산성 화합물을 각기 산 또는 염기로 처리하여 이의 염으로 전환시킴을 특징으로 하는 일반식(Ⅰ)의 1,4-디히드로피리딘 및 이의 염의 제조방법.
    상기식에서, R1은 H,A,Ar-알킬, AO-알킬, ArO-알킬, Ar-알킬-O-알킬 또는 R7R8N-알킬이고, R2및 R6는 각기 H,A,Ar-알킬, Hal-알킬, CF3,R9OCH2-, R7R8N-(CH2)a-CHR10, R11SOm-CH2-, CN 또는 유리 또는 기능적으로 변형된 CHO 그룹이고 R3및 R5는 각기 R12CO-, R11SO2-, (AO)2PO-, NO2또는 CN이고, R4는 4-R13-5-R16-2-티아졸일 또는 4-R13-5-R16-2-티아졸일아미노이고, R7은 H,A,Ar,AOOC-, Ar-알킬-OOC-, R10NHCO-R11SO2- 또는 Ac이고, R8은 H,A, 또는 Ar-알킬이고, R7및 R8은 함께 Z1-COCH2CH2CO-, -COCH=CHCO- 또는 -CO-(O-C6H4)-CO-이고, R9은 H,A,Ar,Ar-알킬, AO-알킬, R7R8N-알킬, Ac, R10NHCO-, R11SO2- 또는 CF3SO2-이고, R10은 H,A 또는 Ar이고, R7및 R10은 함께 또한 탄소수 2내지 4의 알킬렌이고, R11은 A 또는 Ar이고, R12는 HO, AO, R14-알킬-O-, Z=OH-O-, A,Ar,Het,R7R8N- 또는 R15O-알킬-NH-이고, R9및 R12, R8및 R12는 각 경우 함께 또한 결합이고, R13및 R16은 각기 H,A,AOOC,AOOCCH2,H2NCO, ANHCO,A2NCO,HOOC,Ar-알킬, Het, 또는 A,AO,ASOm-, Hal,CF3,HO, O2N, R7R8N, CN, H2NCO, H2NSO2, CHF2-O-, R7R8N-알킬-O-, Ar 또는 ArO로 일치환 내지 삼치환 될수 있는 페닐 그룹이고, R14는 AO,ArO,Ar-알킬-O-, R7R8N-, R11SO2O- 또는 (AO)2PO-O-이고, R15는 H,A,Ar 또는 Ac이고, R17은 HO,AO 또는 A2N이고, a 및 m은 각기 0,1 또는 2이고, m은 0 또는 1이고, A는 탄소수 1내지 20의 선형 또는 분지, 포화 또는 불포화된, 지방족 또는 지환족 탄화수소 래디칼이고, Ac는 R10CO-, Ar-알킬-CO- 또는 Ar-알케닐-CO-이고, Ar은 페닐; A,AO,AcO,Hal,CF3,HO,O2N,H2N,ANH,A2N,AcNH,AOOCNH-, Ar-알킬, OOCNH-, CH-, H2NCO,HOOC,AOOC,H2NSO2및/또는 R11NHCONH-로 일치환 내지 삼치환된 페닐; 또는 나프틸이고, Hal은 F,Cl,Br 또는 I 이고, X는 Cl,Br,I, 또는 유리 또는 반응성 에스테르화 OH 그룹이고, Het은 1내지 4의 산소, 질소 및/또는 황원자를 함유하고, A,AO,Hal,CF3,HO,O2N,H2N,NHA,NA2,AcNH,ASOm, AOOC,CN,H2NCO, HOOC, H2NSO2, ASO2NH, Ar, Ar-알케닐 및/또는 피리딜로 일치환 또는 다치환 될수 있는, 5-원 또는 6-원, 일핵 또는 다핵 헤테로 사이클릭 래디칼, 또는 1-R1-2-R2-3-R3-5-R5-6-R6-1,4-디히드로-4-피리딜이고, Z는 탄소수 4 또는 5이고, O,NH,AN,ArN,Ar-알킬-N,Ar2CHN 또는 AcN으로 차단될수 있는 알킬렌 쇄이며,알킬 또는 알케닐은 각기 탕소수 1내지 4의 알킬렌 또는 알케닐렌쇄이다.
  2. 제1항에 있어서, 다음의 디히드로피리딘을 제조하는 방법.
    (a) 2,6-디메틸-3,5-디메톡시카보닐-4-o-(4-페닐-2-티아졸일아미노)-페닐-1,4-디히드로피리딘; (b) 2,6-디메틸-3,5-디에톡시카보닐-4-o-(4-p-클로로페닐-2-티아졸일아미노)-페닐-1,4-디히드로피리딘; (c) 2,6-디메틸-3,5-디메톡시카보닐-4-o-[4-(3,4-디클로로페닐)-2-티아졸일아미노]-페닐-1,4-디히드로피리딘; (d) 2,6-디메틸-3,5-디메톡시카보닐-4-o-(4-p-플루오로페닐-2티아졸일아미노)-페닐-1,4-디히드로피리딘; (e) 2,6-디메틸-3, 5-디메톡시카보닐-4-o-(4-p-페닐-2-티아졸일아미노)-페닐-1,4-디히드로피리딘; (f) 2,6-디메틸-3,5-디메톡시카보닐-4-o-(4-m-트리플루오로메틸페닐-2-티아졸일아미노)-페닐-1,4-디히드로피리딘; (g) 2,6-디메틸-3,5-디에톡시카보닐-4-o(4-m-클로로페닐-2-티아졸일아미노)-페닐-1,4-디히드로피리딘; (h) 2,6-디메틸-3,5-디메톡시카보닐-4-o-(4-p-톨일-2-티아졸일아미노)-페닐-1,4-디히드로피리핀.
  3. 일반식(Ⅰ)의 화합물 및/또는 이의 생리학적으로 허용가능한 염을 적어도 하나의 고체, 액체 또는 반-액체 부형제 또는 보조제와 함께, 필요시, 하나 또는 그 이상의 다른 활성 화합물과 혼합하여 약학적 용량 형태로 전환시킴을 특징으로 하는 약학적 제형의 제조방법.
  4. 적어도 하나의 일반식(Ⅰ)의 화합물 및/또는 이의 생리학적으로 허용 가능한 염을 함유하는 것을 특징으로 하는 약학적 제형.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR870000300A 1986-01-17 1987-01-16 1,4-디히드로피리딘의 제조방법 KR870007120A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19863601196 DE3601196A1 (de) 1986-01-17 1986-01-17 1,4-dihydropyridine
DEP3601196.7 1986-01-17

Publications (1)

Publication Number Publication Date
KR870007120A true KR870007120A (ko) 1987-08-14

Family

ID=6292010

Family Applications (1)

Application Number Title Priority Date Filing Date
KR870000300A KR870007120A (ko) 1986-01-17 1987-01-16 1,4-디히드로피리딘의 제조방법

Country Status (9)

Country Link
US (1) US4766213A (ko)
EP (1) EP0237695A3 (ko)
JP (1) JPS62181277A (ko)
KR (1) KR870007120A (ko)
AU (1) AU596627B2 (ko)
DE (1) DE3601196A1 (ko)
HU (1) HU198205B (ko)
IE (1) IE870134L (ko)
ZA (1) ZA87327B (ko)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514693A (en) * 1988-12-15 1996-05-07 Farmitalia Carlo Erba S.R.L. Imidazolyl and pyridyl derivatives of phenyl substituted 1,4-dihydropyridines and process for their preparation
ZA906583B (en) * 1989-08-21 1991-09-25 Beth Israel Hospital Method and composition for the treatment of cutaneous,ocular,and mucosal hypersensitivity,inflammatory,and hyperproliferative conditions using topical preparations of nifedipine
US5202331A (en) * 1990-04-18 1993-04-13 Fujisawa Pharmaceutical Co., Ltd. Therapeutic agent for dysuria comprising alpha-phenyl-alpha-pyridylalkanoic acid derivatives
DE4011106A1 (de) * 1990-04-06 1991-10-10 Bayer Ag Neue heterocyclisch substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
AU1422392A (en) * 1991-03-22 1992-10-21 Nippon Soda Co., Ltd. 2-substituted pyridine derivative, production thereof, and agrohorticultural bactericide
GB9119983D0 (en) * 1991-09-19 1991-11-06 Erba Carlo Spa Dihydropyridine derivatives useful in antitumor therapy
US6020348A (en) * 1996-02-01 2000-02-01 Smithkline Beecham Corporation Endothelin receptor antagonists
WO2002051410A2 (en) * 2000-12-22 2002-07-04 Akzo Nobel N.V. Phenylthiazole and thiazoline derivatives and their use as antiparasitics
CN1678608A (zh) * 2002-07-02 2005-10-05 先灵公司 新的神经肽yy5受体拮抗剂
DK1599468T3 (da) 2003-01-14 2008-02-04 Arena Pharm Inc 1,2,3-trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser forbundet dermed såsom diabetes og hyperglykæmi
AU2004247013B2 (en) * 2003-05-14 2010-07-08 Neurogenetic Pharmaceuticals, Inc. Compounds and uses thereof in modulating amyloid beta
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
TW200519091A (en) * 2003-09-10 2005-06-16 Synta Pharmaceuticals Corp Dihydropyridine compounds for treating or preventing metabolic disorders
DK1756084T3 (da) * 2004-06-04 2009-03-23 Arena Pharm Inc Substituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser beslægtet dermed
DOP2006000010A (es) 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
MY148521A (en) * 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
GB0503962D0 (en) * 2005-02-25 2005-04-06 Kudos Pharm Ltd Compounds
CN101263135A (zh) * 2005-09-16 2008-09-10 艾尼纳制药公司 代谢调节剂和代谢相关病症的治疗
PE20071079A1 (es) * 2005-11-15 2007-12-16 Cytokinetics Inc Compuestos de piperidina como inhibidores de la proliferacion celular
TW200811147A (en) * 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
TW200811140A (en) * 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
US20080089947A1 (en) * 2006-08-18 2008-04-17 Knox Clayton D Calcium Influx Inhibitors in the Treatment of Ischemia
WO2008140810A1 (en) * 2007-05-11 2008-11-20 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
US20110105436A1 (en) * 2008-03-10 2011-05-05 Auckland Uniservices Limited Heteroaryl compounds, compositions, and methods of use in cancer treatment
ES2937386T3 (es) 2010-01-27 2023-03-28 Arena Pharm Inc Procesos para la preparación de ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3-il)acético y sales del mismo
SG188548A1 (en) 2010-09-22 2013-04-30 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP3242666A1 (en) 2015-01-06 2017-11-15 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2508181A1 (de) * 1975-02-26 1976-09-09 Bayer Ag 1,4-dihydropyridincarbonsaeurearal- kylester, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
NZ201395A (en) * 1981-07-30 1987-02-20 Bayer Ag Pharmaceutical compositions containing 1,4-dihydropyridines and certain of these dihydropyridines
DE3207982A1 (de) * 1982-03-05 1983-09-08 Bayer Ag, 5090 Leverkusen Neue 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihrer verwendung in arzneimitteln
ATE20064T1 (de) * 1982-07-22 1986-06-15 Pfizer Anti-ischaemische und antihypertensive dihydropyridin-derivate.
IL78642A0 (en) * 1985-05-03 1986-08-31 Pfizer Dihydropyridines and pharmaceutical compositions containing them
GB8527698D0 (en) * 1985-11-09 1985-12-11 Pfizer Ltd Dihydropyridine antiischaemic & antihypertensive agents

Also Published As

Publication number Publication date
EP0237695A3 (de) 1988-12-28
US4766213A (en) 1988-08-23
HU198205B (en) 1989-08-28
ZA87327B (en) 1987-08-26
JPS62181277A (ja) 1987-08-08
DE3601196A1 (de) 1987-07-23
AU596627B2 (en) 1990-05-10
HUT46912A (en) 1988-12-28
AU6720087A (en) 1987-07-23
EP0237695A2 (de) 1987-09-23
IE870134L (en) 1987-07-17

Similar Documents

Publication Publication Date Title
KR870007120A (ko) 1,4-디히드로피리딘의 제조방법
NO177535C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive peptidforbindelser
KR900018098A (ko) 피리돈 카르복실산과 항균제
EP0237051A3 (en) Prodrug compounds, process for the preparation thereof and sustained release preparation comprising the same
KR880013888A (ko) 신규 디티오아세탈 화합물, 그의 제조방법 및 이 화합물로 되는 제약 조성물
KR830010103A (ko) 카르복시미드 유도체 및 그것을 함유하는 의약의 제조방법
KR870002078A (ko) 에틸렌디아민 모노아미드유도체의 제조방법
DK570689A (da) Imidazolderivater
KR860000248A (ko) N-아실 산성 아미노산 디아미드 유도체의 제조방법
ES345981A1 (es) Procedimiento para la obtencion de alimentos para aves.
KR870008836A (ko) 디페닐-메탄 유도체 및 제약상 용도
KR840008023A (ko) 크로몬-및 티오크로몬-치환된 1,4- 디하이드로피리딘유도체의 제조방법
KR900007858A (ko) 페닐알리파틸 아미노 알칸디포스폰산
KR840000534A (ko) 디히드로피리딘 화합물류의 제조방법
KR860007266A (ko) 알켄아미도 세팔로스포린 에스테르의 제조방법
GB1473435A (en) Reactive dyestuffs
KR840007869A (ko) N-아미노피리디늄 베타인의 신규 유도체 및 그 제조방법과 이를 함유한 약제학적 조성물
KR900009661A (ko) 에르골린 유도체
DE3661198D1 (en) Phosphate ester derivatives, and their use as anti-cancer agents
KR890002002A (ko) I,4-디히드로피리딘
KR910015301A (ko) 수면 무호흡증의 치료방법
EP0223512A3 (en) 2-pyridylacetic acid derivative, preparation process thereof and pharmaceutical composition containing the same
GB8515212D0 (en) Thiazolidine derivatives
KR850001204A (ko) 1,4-디하이드로피리딘 유도체의 제조방법
KR880007502A (ko) 신규의 아미노알카노일-디벤조[d, g][1,3,6]디옥사조신 및 그의 제조방법

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid